Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-FOLFOXIRI phase 1 study in advanced gastric cancer
jRCTs041240169Phase 1Recruiting
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab, zolbetuximab, trastuzumab and pembrolizumab in gastric cancer (GC) and gastric adenocarcinoma (4 cohorts). Primary endpoint: Incidence of dose-limiting toxicity. Started Mar 2025; status: recruiting.
02
Drugs
03
Conditions
gastric cancer (GC)gastric adenocarcinoma
Beyond the preview
Go deeper on jRCTs041240169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041240169.